ARTICLE | Product Development
Alzheimer’s prevention replays the same amyloid failures as the treatment setting
Lilly’s solanezumab, Roche’s gantenerumab miss DIAN-TU endpoint in presymptomatic AD patients
February 11, 2020 1:17 AM UTC
Updated on Feb 11, 2020 at 2:16 AM UTC
The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain in development.
On Monday, Eli Lilly and Co. (NYSE:LLY) and Roche (SIX:ROG; OTCQX:RHHBY) announced that the anti-amyloid therapies solanezumab and gantenerumab each missed the primary endpoint of slowing cognitive decline in the investigator-led study, which enrolled presymptomatic patients carrying mutations that cause autosomal dominant Alzheimer’s disease (ADAD). ...
BCIQ Target Profiles